Thrivent Financial for Lutherans Sells 12,680 Shares of Illumina, Inc. (NASDAQ:ILMN)

Thrivent Financial for Lutherans cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 20.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,069 shares of the life sciences company’s stock after selling 12,680 shares during the period. Thrivent Financial for Lutherans’ holdings in Illumina were worth $6,647,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Golden State Wealth Management LLC acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $32,000. Versant Capital Management Inc boosted its position in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in Illumina in the 4th quarter valued at $45,000. Assetmark Inc. raised its position in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Finally, TD Private Client Wealth LLC lifted its stake in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on ILMN shares. Royal Bank of Canada lowered their price objective on Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a research report on Wednesday, March 12th. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Morgan Stanley dropped their price target on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Guggenheim reduced their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Robert W. Baird lowered their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Trading Up 3.4 %

NASDAQ:ILMN opened at $87.66 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The business’s 50-day simple moving average is $108.20 and its 200-day simple moving average is $128.26. Illumina, Inc. has a fifty-two week low of $80.18 and a fifty-two week high of $156.66. The stock has a market capitalization of $13.89 billion, a PE ratio of -11.41, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.